49results about How to "Low side reaction rate" patented technology

The invention relates to a preparation method of a single crystal lithium-rich manganese-based anode material. In the process of preparing a single crystal lithium-rich manganese-based anode materialby calcining a lithium-rich manganese-based material precursor, the method comprises the following steps: S1, firstly, pre-sintering the lithium-rich manganese-based material precursor, and carrying out crushing treatment to obtain scattered oxide of the lithium-rich manganese-based material precursor; S2, uniformly mixing the oxide of the lithium-rich manganese-based material precursor with a lithium source and then sintering to obtain the oxide of the lithium-rich manganese-based material precursor. More preferably, a small amount of additive is mixed while mixing lithium after pre-sinteringand crushing; and the mixed additive may induce crystal growth and grain boundary fusion, which is favorable for forming a single crystal and improving the structure of the crystal; pre-sintering andcrushing can reduce the particle diameter to a relatively desirable range, so that the sintered body has better kinetic performance and achieves better mixing uniformity when mixing lithium and mixing the additive, to promote the formation of the single crystal. By means of such a preparation method, a lithium-rich manganese-based anode material having a high degree of single crystallization anda uniform particle diameter can be obtained.

The invention relates to a kind of hydrophobia vaccine for human, which in detail relates to a freeze-drying hydrophobia vaccine for human and its preparation method. It is contained in physiological soluble buffer solution with pH being 7-8, the sodium chloride weight proportion is 0.4-1.0%, one or several from mycose, sucrose, gelatin, maltose and dextran is used as stabilizing agent, the concentration is 0.5-5%; the weight proportion of shaping agent for freeze-drying agent is 1-5%, and the purified hydrophobia viral antigen concentration is 4-20 IU per ml.

A charging method, a charging device executing the charging method, a terminal and a readable storage medium are provided. The charging method includes the steps of in a first stage, charging, with afirst stage current, a battery to a first stage voltage; and in a second stage, charging, with a second stage current, the battery to a second stage voltage, wherein the second stage voltage is greater than the first stage voltage, and the second stage current is less than the first stage current. The charging method can shorten the time during which the cathode of a lithium battery is at a high potential during the charging process, thereby prolonging the service life of the lithium battery and shortening the charging time.

The invention relates to an anticholinergic pharmaceutical composition. Specifically, the invention relates to a medicament capable of being used in pharmacy, wherein the,medicament comprises a compound expressed by the following formula. The invention further provides a preparation of the medicament, and the medicament and the preparation are used as an anticholinergic medicament and can be clinically used for anesthesia, peptic ulcer, salivation, etc. The raw material medicament or preparation has the function of inhibiting gastric secretion and regulating gastrointestinal peristalsis; the raw material medicament or preparation has relatively strong salivary secretion resistance than atropine while having no central anticholinergic activity. The anticholinergic pharmaceutical composition is generally used for clinically treating such symptoms as gastric and duodenal ulcer, chronic gastritis and excessive secretion of gastric acid.

The invention relates to a triple compound microsphere vascular targeted embolization sustained-release preparation containing an antituberculous drug as well as a preparation method and application of the preparation. The sustained-release agent comprises a carrier and drugs, wherein the drugs are coated with the carrier; the carrier is sodium alginate or chitosan, and the drugs are triple antituberculous compound drugs including rifampicin, isoniazid and pyrazinamide or moxifloxacin. The three antituberculous drugs are matrix drug solutions, the sodium alginate or chitosan is a carrier solution, the matrix drug solutions and the carrier solutiona are mixed to prepare a solution, the polymer solution containing drugs is dispersed into fogdrops with a certain diameter by adopting a high-voltage electrostatic droplet mode, and the fogdrops are sprayed into a solidifying liquid to prepare antituberculous drug microspheres under the action of calcium ions. The embolization sustained-release preparation can be used for treating tuberculosis, massive hemoptysis of pulmonary tuberculosis, tuberculosis cavity, renal tuberculosis, osteoarticular tuberculosis, genital tuberculosis, tuberculosis of thyroid gland, tuberculosis of cervical lymph nodes, tuberculosis of pericardium, tuberculosis of chest wall, pleural tuberculosis and other kinds of tuberculosis in a body.

The invention relates to a medicinal bulk drug for resisting tumors, and in particular relates to a bulk drug for medicines. The active component of the bulk drug is a compound in the formula I or pharmaceutical salt thereof, wherein each substituent is described as the specification. The invention also relates to a medicinal composition containing the compound in the formula I or salt thereof, a preparation method of the medicinal composition and pharmaceutical application thereof. The bulk drug has excellent characteristics, such as stability and safety, when serving as an anti-tumor drug.

The invention discloses long-acting recombinant human brain natriuretic peptide fusion protein (hBNP-Fc) and a preparation method thereof. An amino acid sequence of the fusion protein sequentially comprises human BNP (hBNP), peptide connectors and human IgG4Fc variants from N to C. The fusion protein has a biological activity similar to or higher than that of rhBNP, a longer half-life period and fewer side effects. The invention also relates to the application of a recombinant hBNP-Fc fusion protein composition in the preparation of acute heart failure treatment and/or prevention medicine.

The invention relates to a famotidine composition prepared by a freeze-drying method for injection. The famotidine composition comprises famotidine, mannitol and aspartate; water content of the composition is lower than 5%; the composition is dissolved into solution with concentration 1mg/ml by water for injection and pH value of the solution ranges from 4.5 to 6.0. The composition is prepared by the steps of weighing a certain dosage of famotidine, mannitol and aspartate according to a formula, adding in an appropriate amount of water for injection, stirring to dissolve the components, adding in activated carbon with stirring and then removing the carbon by filtering, replenishing water for injection to full dose of the formula, stirring uniformly to obtain a solution, measuring/regulating pH value of the solution to 4.5-6.0, sterilizing and filtering the solution to obtain liquid medicine, filling the liquid medicine in penicillin bottles, and finally removing water content by the freeze drying method and plugging the bottles. The famotidine composition prepared by the freeze-drying method for injection has excellent pharmaceutical property.

The invention relates to a vascular targeting embolism sustained release agent of a triple compound microsphere for an antituberculosis drug, a preparation method and applications thereof. The sustained release agent comprises a carrier and a drug, wherein the drug is encapsulated by the carrier, the carrier is selected from sodium alginate or chitosan, and the drug is a triple compound antituberculosis drug which comprises rifampin, isoniazide and pyrazinamide or moxifloxacin. Three antituberculosis drugs are employed as matrixes of a drug solution, sodium alginate or chitosan is used as a carrier solution, and a prepared solution is obtained by mixing the drug solution and the carrier solution. A polymer solution having the drug is enabled to be dispersed into droplets with certain particle sizes and to be sprayed into a curing liquid through a method of high voltage electrostatic droplets, and thus the microsphere for the antituberculosis drug are prepared in the presence of calcium ions. The embolism sustained release agent can be used in the drug for treating pulmonary tuberculosis, pulmonary tuberculosis massive hemoptysis, cavitary pulmonary tuberculosis, renal tuberculosis, osteoarticular tuberculosis, genital tubercolosis, thyroid tuberculosis, tuberculosis of cervical lymph nodes, pericardial tuberculosis, chest-wall tuberculosis and other in-vivo tuberculosises.

The invention provides a water-based hydroxy acrylic resin dispersion and a preparation method thereof. The water-based hydroxy acrylic resin dispersion is prepared from the following raw materials inparts by weight: 15-25 parts of a hydrophilic solvent, 3-8 parts of a functional carboxyl monomer, 10-30 parts of a hydroxyl-containing monomer, 30-50 parts of an acrylate monomer, 10-20 parts of a vinyl monomer, 3-10 parts of an initiator, 1-4 parts of a basic compound, and 80-120 parts of deionized water; wherein the functional carboxyl monomer contains a secondary amino group and a long-chaincarboxyl group. According to the invention, the stability and water resistance of the water-based hydroxy acrylic resin dispersion are improved, the drying speed of the coating can be increased, the probability of side reaction with isocyanate is reduced, and the defects of a paint film are reduced.

The invention discloses an improved preparation method of tetramethyl ammonium bicarbonate. According to the improved preparation method, dimethyl carbonate and a trimethylamine aqueous solution are taken as reaction raw materials, and tetramethyl ammonium bicarbonate is prepared by adopting a one-step method; wherein the reaction is carried out in the presence of an organic amine modified molecular sieve. The organic amine modified molecular sieve with a specific proportion is added, so that the product yield is further improved. The organic amine modified molecular sieve interacts with dimethyl carbonate or a product thereof, so that the probability of side reaction of the final product is reduced.

The invention provides a preparation method of TGEV (transmissible gastroenteritis virus). According to the method, in a bioreactor, an ST cell is adopted as the host cell, microcarrier culture is employed for proliferation of TGEV, and at the same time efficient condition parameters are designed. The culture efficiency is significantly improved, the cell density is enhanced by 3-5 times than spinner bottles, the virus titer is high, and is increased from the 10<7.0-7.3>TCID50/ml of spinner bottle technique to 10<7.7>-10<8.5>TCID50/ml, and the titer is enhanced by 5-10 times. At the same time, a high titer antigen needs a high dilution factor during use, so that the content of heterologous protein in a unit volume antigen is reduced indirectly, thereby lowering the side reaction incidence of vaccines prepared with heterologous protein as the antigen. The technology is low in cost, and compared with the practice of selecting a traditional basic medium, the harvest time is greatly shortened, the interassay difference is small, and the process is stable.

The invention provides a preparation method of acetic acid 2-hydroxyl-3-chloro-propyl ester. The invention provides the acetic acid 2-hydroxyl-3-chloro-propyl ester generated by reacting acetic acid with epichlorohydrin by a phase transfer catalyst. The preparation method of a substance comprises the following steps: under the condition that the molar ratio of the acetic acid to the epichlorohydrin is 1 to (1.02 to 1.05), adding the catalyst, and controlling the reaction temperature at 105 to 110 DEG C for 3 hours; then controlling the temperature at 115 to 125 DEG C for 3 hours; under the conditions that the temperature is 100 to 105 DEG C and the pressure is 0.04 to 0.06 MPa, vacuumizing for 2 hours to obtain high-purity acetic acid 2-hydroxyl-3-chloro-propyl ester. The catalyst is the phase transfer catalyst, preferable quaternary ammonium salt but not limited to didoctyl dimethyl ammonium bromide and benzyl triethyl ammonium in quaternary ammonium salt; the use amount of the preferable quaternary ammonium salt is 2 to 3 percent of the total amount in the step. The acetic acid 2-hydroxyl-3-chloro-propyl ester prepared by the preparation method has the advantages of high conversion rate, high selectivity, good stability and suitability for industrial production.

The invention belongs to the technical field of medicine, and relates to a medicinal meclofenoxate hydrochloride composition freeze-dried powder injection for treating senile dementia. The medicinal meclofenoxate hydrochloride composition freeze-dried powder injection for treating senile dementia comprises meclofenoxate hydrochloride and an excipient. The excipient is trehalose, the meclofenoxate hydrochloride is a novel crystal complex, and an X-ray powder diffraction pattern measured by adopting Cu-Ka rays is shown as Figure 1. The novel crystal structure of the meclofenoxate hydrochloride is different from the prior art, the experimental verification shows that compared with the prior art, the moisture absorption performance and mobility of the meclofenoxate hydrochloride crystal complex are obviously improved, the content of moisture and impurities is relatively low, the stability is better, and convenience is brought to the preparation of a formulation; the bioavailability is higher, and the adverse reaction is reduced. Compared with the prior art, the freeze-dried powder injection prepared by using the meclofenoxate hydrochloride crystal complex is good in stability, extremely low in moisture and impurity content, low in adverse reaction, good in stability after being compounded with solvent, extremely low in content of insoluble micro-particles and very suitable for the clinical application.

The invention provides a high polymer micro negative pressure thermal cracking method for waste tires. Particularly, blocky tires are subjected to two-stage smashing directly, smashed materials are injected into a micro hole plate inside a kettle body through a pipe embedded into a reaction kettle, then, the kettle body is closed, at first, low speed temperature rise is performed under the micro negative pressure condition to reach about 120 DEG C for a period of time and the high temperature increase speed is adopted for increasing temperature to 450 DEG C under deep negative pressure condition, nitrogen protection is performed, continuous pyrolysis is performed under the pressure reduction condition, oil obtained after pyrolysis can be discharged downwards through the micro hole plate under the pressurizing condition, a solid phase remains on the micro hole plate, after drying and grinding are performed, and existing metal wires in tires exist in a granular or sheet shape, and can beremoved through screening. By applying the method, the whole process of smashing, pyrolyzing and collecting tires can be completed at a time, the metal wire stripping link is omitted, and the continuity and technological efficiency of the pyrolysis technology are obviously improved.

The invention belongs to the technical field of medicine, and relates to a medicinal meclofenoxate hydrochloride composition freeze-dried powder injection for treating traumatic coma. The medicinal meclofenoxate hydrochloride composition freeze-dried powder injection for treating traumatic coma comprises meclofenoxate hydrochloride and an excipient. The excipient is a low-molecular dextran, the meclofenoxate hydrochloride is a novel crystal complex, an X-ray powder diffraction pattern measured by using Cu-Ka rays is shown as figure 1, and the meclofenoxate hydrochloride is the meclofenoxate hydrochloride different from that reported in the prior art. The experiment shows that compared with the prior art, the moisture absorption performance and mobility of the meclofenoxate hydrochloride novel crystal complex are obviously improved, the content of moisture and impurities is extremely low, the stability is better, and convenience is brought to the preparation of a formulation; moreover, the bioavailability is higher, and adverse reaction is reduced. Compared with the prior art, the freeze-dried powder injection prepared by using the novel complex is good in stability, extremely low in moisture and impurity content, low in adverse reaction, good in stability after being compounded with solvent, extremely low in content of insoluble micro-particles and very suitable for the clinical application.

The invention provides health-care liquor for treating rheumatic arthritis. The health-care liquor is prepared from the following raw materials in parts by weight: 60 parts of waxberry pulp, 30-50 parts of grape pulp, 10-30 parts of ciliate desert-grass, 5-15 parts of cornu cervi pantotrichum, 20-30 parts of carthamus tinctorius, 10-20 parts of rhodiola rosea, 15-35 parts of radix aconiti, 10-20 parts of myrrh, 5-15 parts of yeast liquid and 1-5 parts of honey. Compared with the prior art, the health-care liquor is low in cost and simple in technology, can effectively assist in treating the rheumatic arthritis and obviously reduce the incidence of side effects and has significant effects.